PharmaEngine

PharmaEngine Enterprise Value

The Enterprise Value (EV) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 9.22 B TWD. In the previous year, Enterprise Value (EV) was 9.22 B TWD — a change of -0.08% (lower).

Enterprise Value

9.22 BTWD

YoY

-0.08%

Last updated:

Enterprise Value (EV) of PharmaEngine is 2025 9.22 B TWD. Enterprise Value (EV) of PharmaEngine was 2024 9.22 B TWD. It decreases by -0.08% lower compared to the previous year.

The PharmaEngine Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
5.55 B TWD
Jan 1, 2019
5.83 B TWD
Jan 1, 2020
5.85 B TWD
Jan 1, 2021
5.41 B TWD
Jan 1, 2022
5.58 B TWD
Jan 1, 2023
5.60 B TWD
Jan 1, 2024
9.22 B TWD
Jan 1, 2025
9.22 B TWD
The PharmaEngine Enterprise Value history
YEAREnterprise ValueYoY
9.22 BTWD-0.08%
9.22 BTWD+64.61%
5.60 BTWD+0.46%
5.58 BTWD+3.09%
5.41 BTWD-7.43%
5.85 BTWD+0.19%
5.83 BTWD+5.04%
5.55 BTWD-6.48%
5.94 BTWD+11.88%
5.31 BTWD-12.47%
6.06 BTWD-4.02%
6.32 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Enterprise Value (EV) of PharmaEngine is 9.22 B TWD in 2025.

Enterprise Value (EV) of PharmaEngine changed from 9.22 B TWD to 9.22 B TWD, representing a -0.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s TWD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' TWD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PharmaEngine

All Key Metrics — PharmaEngine